 |
mhuckman |
11/20/2009 12:30:01 PM ET |
|
More on the Arbiter arbitration. $MRK $ABT http://bit.ly/5MBwQf |
|
|
TraderFlorida |
11/18/2009 8:00:01 PM ET |
|
http://chart.ly/cxnr8m $MRK - Broke out today on heavy vol. could see much higher prices from here |
|
|
mhuckman |
11/16/2009 7:00:01 AM ET |
|
Leerink Swann's Seamus Fernandez on Arbiter $MRK $ABT: "Good for Niaspan, not terrible for Zetia." |
|
|
mhuckman |
11/16/2009 6:00:01 AM ET |
|
JPMorgan's Chris Schott on Arbiter impact on Merck's$MRK Vytorin-Zetia sales: "Commercial Risk: Appears Limited; Watching Media Uptake." |
|
|
mhuckman |
11/15/2009 6:30:00 PM ET |
|
Niaspan beats Zetia. $MRK $ABT Niaspan cut plaque, Z didn't. "Significantly" more CV events w/Z. |
|
|
mhuckman |
11/14/2009 7:30:00 AM ET |
|
Ahead of Arbiter (Niaspan vs Zetia/Vytorin) study results Merck $MRK issues PR about commitment to heart disease. http://tinyurl.com/pmmrkcv |
|
|
mhuckman |
11/14/2009 7:30:00 AM ET |
|
Merck's $MRK VP of Clinical Research also writes letter to the editor @ NYT re Arbiter story yesterday. http://tinyurl.com/pmnytarb |
|
|
mhuckman |
11/9/2009 8:00:00 AM ET |
|
Leerink Swann's Seamus Fernandez ups Merck $MRK 2 Outperform: "We recommend investors use near-term liquidity 2 build, or add to, position." |
